They also highlight the need for additional mutations in addition to c-myc deregulation to accelerate B-cell lymphoma development and that these “hits” target both proliferative, apoptotic and cytokine pathways. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.